Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Begum Ozdengulsun"'
Autor:
Guray Saydam, Ali Unal, Ibrahim Celalettin Haznedaroglu, Abdullah Hacihanifioglu, Ozgur Mehtap, Erdal Kurtoglu, Mesut Gocer, Mehmet Turgut, Engin Kelkitli, Memis Hilmi Atay, Nil Guler, Basak Unver Koluman, Mehmet Sonmez, Nergiz Erkut, Emin Kaya, Irfan Kuku, Mehmet Ali Erkurt, Gulsum Ozet, Funda Ceran, Fahri Sahin, Nur Soyer, Meliha Nalcaci, Mehmet Yilmaz, Sirac Bozkurt, Birkan Aver, Begum Ozdengulsun, Egemen Ozbilgili, Osman Ilhan
Publikováno v:
International Journal of Hematologic Oncology. 11
This study aimed to identify patient characteristics, treatment patterns and outcomes and to evaluate the effects of presence of comorbidities at diagnosis in chronic phase (CP)-chronic myeloid leukemia (CML) patients in Turkey.Hospital records betwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7d3c2db11c324a5197b8a9728140fed
https://doi.org/10.2217/ijh-2021-0008
https://doi.org/10.2217/ijh-2021-0008
Autor:
Guray, Saydam, Ridvan, Ali, Ahmet Muzaffer, Demir, Ahmet Emre, Eskazan, Birol, Guvenc, Ibrahim Celalettin, Haznedaroglu, Mehmet Ali, Ozcan, Ozan, Salim, Mehmet, Sonmez, Ayse Tulin, Tuglular, Mehmet, Turgut, Ali, Unal, Birkan, Aver, Sirac, Bozkurt, Begum, Ozdengulsun, Osman, Ilhan
Publikováno v:
International journal of hematologic oncology. 11(1)
Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59a65debb8e05495f382dcafff8e2000
https://pubmed.ncbi.nlm.nih.gov/35664044
https://pubmed.ncbi.nlm.nih.gov/35664044